Orforglipron(Orforglipron) - 药物靶点：GLP-1R_在研适应症：高血压，阻塞性睡眠呼吸暂停综合征，动脉粥样硬化_专利_临床

概要

基本信息

药物类型

小分子化药

别名

GLP-1R NPA、LY-3502970、LY3502970

+ [1]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [3]

在研适应症

高血压阻塞性睡眠呼吸暂停综合征动脉粥样硬化+ [8]

非在研适应症-

原研机构

Chugai Pharmaceutical Co., Ltd.

在研机构

Eli Lilly & Co.

Chugai Pharmaceutical Co., Ltd.

非在研机构-

权益机构

Eli Lilly & Co.

Chugai Pharmaceutical Co., Ltd.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C48H48F2N10O5

InChIKeyUSUWIEBBBWHKNI-KHIFEHGGSA-N

CAS号2212020-52-3

关联

39

项与 Orforglipron 相关的临床试验

NCT06972459

/ Recruiting临床3期

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO.
Participation in the study will last about 18 months.

开始日期2025-05-15

申办/合作机构

Eli Lilly & Co.

NCT06948422

/ Recruiting临床3期

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

开始日期2025-04-30

申办/合作机构

Eli Lilly & Co.

NCT06824051

/ Active, not recruiting临床1期

A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

开始日期2025-02-17

申办/合作机构

Eli Lilly & Co.

100 项与 Orforglipron 相关的临床结果

登录后查看更多信息

100 项与 Orforglipron 相关的转化医学

登录后查看更多信息

100 项与 Orforglipron 相关的专利（医药）

登录后查看更多信息

42

项与 Orforglipron 相关的文献（医药）

2025-06-21·NEW ENGLAND JOURNAL OF MEDICINE

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

Article

作者: Eyde, Sarah ; Denning, Max ; Fernández Landó, Laura ; Rosenstock, Julio ; Chen, Yanyun ; Ludwig, Lisa ; Nevarez Ruiz, Luis ; Liu, Rong ; Cox, David ; Li, Jianghao ; Hsia, Stanley ; Wu, Wen-Shuo

BACKGROUND:

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.

METHODS:

In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. Participants had type 2 diabetes treated only with diet and exercise, a glycated hemoglobin level of at least 7.0% but no more than 9.5%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 23.0. The primary end point was the change from baseline to week 40 in the glycated hemoglobin level. A key secondary end point was the percent change in body weight from baseline to week 40.

RESULTS:

A total of 559 participants underwent randomization. The mean glycated hemoglobin level at baseline was 8.0%. At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 percentage points with the 12-mg dose, -1.48 percentage points with the 36-mg dose, and -0.41 percentage points with placebo. All three doses of orforglipron were superior to placebo with respect to the primary end point; the estimated mean difference from placebo was -0.83 percentage points (95% confidence interval [CI], -1.10 to -0.56) with the 3-mg dose, -1.06 percentage points (95% CI, -1.33 to -0.79) with the 12-mg dose, and -1.07 percentage points (95% CI, -1.33 to -0.81) with the 36-mg dose (P<0.001 for all comparisons). The mean glycated hemoglobin level at week 40 was 6.5 to 6.7% with orforglipron. The percent change in body weight from baseline to week 40 was -4.5% with the 3-mg dose, -5.8% with the 12-mg dose, -7.6% with the 36-mg dose, and -1.7% with placebo. The most common adverse events were mild-to-moderate gastrointestinal events, most of which occurred during dose escalation. No episodes of severe hypoglycemia were reported. Permanent discontinuation of orforglipron or placebo due to adverse events occurred in 4.4 to 7.8% of participants receiving orforglipron and 1.4% of participants receiving placebo.

CONCLUSIONS:

In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971940.).

2025-06-01·Diabetes Technology & Therapeutics

Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis

Review

作者: Zhang, Xianhua ; Li, Jueyu ; Ma, Xiangyu ; Jin, Siyao ; Zhao, Libo ; Xu, Jiamin ; Li, Yanming ; Bing, Hao ; Yu, Boran ; Zhang, Shaolong

The objective of this study is to quantitatively compare the weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adult patients with no diabetes and type 2 diabetes (T2D). PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase have been used as data sources from database inception to January 6, 2024. A total of 137 trials, encompassing 310 treatment arms, 17 GLP-1RAs, and 56,683 patients, were included in the analysis. The included trials were divided into three groups based on the characteristics of the populations: nondiabetic overweight or obesity group (NDOOG), type 2 diabetes Caucasian group (T2DCG), and type 2 diabetes Asian group (T2DAG). The effects of covariates were further evaluated, patients with a higher baseline body weight tend to have better weight loss outcomes, and patients with a higher baseline glycated hemoglobin (HbA1c) tend to achieve better blood sugar control. Five mathematical models were subjected to longitudinal analysis. In terms of Δ body weight, retatrutide (12 mg qw) was the most effective treatment (mean difference = -26.56% [95% confidence interval: -43.89% to -3.01%]). Tirzepatide (15 mg qw) demonstrated good weight loss ability in all three ΔBW models, ΔBW-NDOOG (-22.76% [-26.45% to -18.50%]), ΔBW-T2DCG (-11.09% [-12.39% to -9.44%])), and ΔBW-T2DAG (-4.97% [-5.84% to -4.12%]). In the aspect of ΔHbA1c, tirzepatide (10 mg qw) and oral orforglipron (10 mg qd) were the most effective drug, respectively. GLP-1RAs demonstrated effective weight management in both nondiabetic and T2D populations. Retatrutide achieved the most pronounced weight reduction, followed by tirzepatide. GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.

2025-04-01·DIABETES OBESITY & METABOLISM

Anti‐diabetic effects of GLP‐1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review

Review

作者: Tan, Benjamin Y. Q. ; Poh, Kian Keong ; Kong, William K. F. ; Wong, Hon Jen ; Lin, Norman H. Y. ; Eng, Pei Chia ; Yeo, Leonard L. L. ; Sia, Ching‐Hui ; Chan, Mark Y. ; Toh, Keith Zhi Xian ; Teo, Yao Hao ; Dalakoti, Mayank ; Teo, Yao Neng ; Yeo, Brian S. Y.

Abstract:

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for anti‐obesity indications. However, little is known of the comparative effect of GLP‐1 RAs and their glycemic impact across the different routes of administration, diabetic statuses and durations of prescription. PubMed, EMBASE and CENTRAL were searched from inception to 13 February 2024. Only randomised controlled trials were included in this systematic review and meta‐analysis. Adults aged above 18 years old, who were in the overweight/obesity range, with or without type 2 diabetes mellitus (T2DM) were included. Baseline characteristics and changes in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) were obtained. GLP1‐RAs demonstrated an overall reduction in HbA1c of −0.72% (95% confidence interval [CI] −0.79 to −0.65, p < 0.01) and in FPG of −1.00 mmol/L (95% CI −1.16 to −0.84, p < 0.01). HbA1c reduction in pre‐DM patients was −0.44% (95% CI −0.54 to −0.18, p < 0.01). Patients who were followed up for more than a year experienced a smaller reduction of HbA1c. Meta‐regression showed that the GLP‐1 RAs are more efficacious at higher HbA1c and lower body mass index. Overall, GLP‐1 RAs consistently led to a significant reduction in HbA1c at −0.72% and FPG at −1.00 mmol/L. These effects may be equally efficacious in pre‐DM patients with obesity and those at lower BMI. With pre‐DM and obesity being risk factors for metabolic syndrome, these findings may provide newer perspectives in expanding indications for GLP‐1 RA initiation.

373

项与 Orforglipron 相关的新闻（医药）

2025-07-09

·BioSpace

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn. > Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart While most of the U.S. was celebrating the 4th of July holiday, President Donald Trump was busy signing the One Big, Beautiful Bill into law. This wide-ranging tax law has a few implications for the biopharma industry, including expanded IRA exemptions for orphan drugs . Looking ahead to the second half of 2025, BioSpace reviews some of the upcoming catalysts highlighted by Jefferies’ “Halftime Show” report , including a highly anticipated Phase III readout for Eli Lilly’s oral obesity candidate orforglipron and an eye on rare disease decisions under the “new” FDA. Speaking of FDA decisions, this week kicked off with a surprise approval—that of KalVista’s Pharmaceuticals’ Ekterly for hereditary angioedema. The road to approval for Ekterly was not a smooth one, after the FDA delayed its target action date and Endpoints News reported that FDA Commissioner Marty Makary tried to have the application rejected. More regulatory controversy is afoot as Health Secretary Robert F. Kennedy Jr. is facing yet another lawsuit. A group of medical organizations have sued Kennedy and other health leaders in an attempt to reverse Kennedy’s recent decision to remove COVID-19 shots from the routine immunization guidelines for healthy children and healthy pregnant women. In other vaccine news, Kennedy endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are at risk of severe disease—following the recommendation of the CDC vaccine advisory committee he turfed last month. This seeming reversal of sentiment largely mirrors the Secretary’s massive HHS overhaul , which has already seen several of these layoffs reversed. In ClinicaSpace this week, we take a deep dive into the numbers. Also in ClinicaSpace, we feature four therapies hanging tough in a troubled TIGIT space that has seen several companies burn billions of dollars on failed assets. And BrainStorm Cell Therapeutics is back in the news after signaling support for a Citizens’ Petition submitted to the FDA requesting the approval of its cell therapy NurOwn, whose Biologics License Application was withdrawn in 2023. Finally, in BioPharm Executive , we take a deep dive into the burgeoning longevity space and unpack the short-lived marriage between Novo Nordisk and Hims & Hers Health.

疫苗临床3期细胞疗法上市批准

2025-07-07

·医药投资部落

AI设计的国产小分子GLP-1，给礼来上了压力

现有GLP-1药物（如司美格鲁肽、利拉鲁肽）多为注射剂型，尽管成功的长效化剂型开发，已实现每周一次甚至每月一次的注射频率，但全球真实世界研究显示：因恐针、疼痛或操作不便等各种原因，仅约50%患者能坚持注射治疗1年以上，2年持续使用率降至约30%。鉴于上述原因，对于口服剂型的小分子GLP-1药物的开发，是近年来全球医药行业竞逐的一个热点方向。2025年6月19日，杭州，一家专注于使用人工智能驱动新药研发的公司「德睿智药」宣布，其自主研发的口服小分子GLP-1RA新药MDR-001片，在治疗肥胖或超重适应症的多中心24周IIb期临床试验中，成功达到临床终点。研究结果表明，肥胖或超重受试者在接受MDR-001片治疗24周时，给药组减重高达10.3%，安慰剂组减重为2.5%（P<0.00001），经安慰剂调整后的平均减重范围为-7.1%至-7.8%，且安全性、耐受性优异。口服MDR-001片各剂量组体重较基线降低-8.2%至-10.3%，绝对减重7.4至9.2kg，而安慰剂组仅为2.4kg（P<0.00001）；高达70.9%至85.4%的受试者减重≥5%，34.5%至48.1%受试者减重≥10%。同时，MDR-001在改善多个代谢和心血管疾病相关参数方面表现出色，包括腰围、血脂、血压等指标，有望为患者带来全面的临床获益。就在此前不久的2025年4月，全球医药巨头礼来，也宣布其小分子GLP-1受体激动剂Orforglipron治疗二型糖尿病三期临床试验获得成功。作为这项临床试验的关键次要终点，orforglipron最高剂量组的入组患者，在第40周时，实现平均体重减轻7.3kg（7.9%）。从入组患者的基线体重而言，礼来的这个三期临床试验，入组患者基准体重为90.2公斤，而德睿智药的二期临床试验，入组患者基准体重为90.1公斤，二者极为接近，因此具备非头对头比较的意义。德睿智药的MDR-001片治疗24周时，患者的减重比例就达到了10.3%，超过了礼来orforglipron治疗40周时的7.9%。在2023年，礼来曾经公布过orforglipron的二期临床试验数据，其最高剂量组的减重幅度达到了12.6%，但是该二期临床试验的入组患者的基准体重，达到了108.7公斤，显著超过了德睿智药此次二期临床试验的入组患者90.1公斤的基准体重。除了减重效果之外，优异的安全性是德睿智药MDR-001片所体现的另一个显著优势。事实上，在小分子GLP-1领域，安全性可能是比减重效果更让大家关注的一个核心指标。由于安全性而导致的小分子GLP-1药物研发失败，曾经让不少跨国药企损失惨重。最突出的案例，就是辉瑞公司两款小分子GLP-1受体激动剂的研发失败。2023年6月，因转氨酶升高问题，辉瑞医药的Lotiglipron被终止研发。2023年12月，辉瑞医药的另一款小分子GLP-1药物Danuglipron，其每日两次服用的制剂，因耐受性问题被终止研发。数据显示，这款药物的临床试验中，高达73%的患者出现恶心，47%出现呕吐，25%出现腹泻，停药率超过50%。在2025年4月，Danuglipron每日一次的缓释制剂，因潜在肝损伤风险，也被终止研发。原因是有一名无症状参与者出现了潜在的药物诱导性肝损伤。相比之下，德睿智药MDR-001片，目前读出的安全性数据，堪称优异。试验期间，MDR-001片没有出现药物治疗相关严重不良事件（SAE）。各治疗组主要不良事件为胃肠道反应，包括恶心、呕吐和腹泻，多为轻中度且集中发生在滴定期前6周内, 中位恢复时间约为1-5天。同时，受试者整体肝脏方面安全性表现良好，值得注意的是，本研究给药组纳入了约20%既往病史肝功能异常和转氨酶升高的受试者，各组未观察到转氨酶升高的趋势，且相比安慰剂组，MDR-001治疗组的转氨酶较基线均有明显降低。整个MDR-001片的二期临床试验，仅有2例（0.8%）因治疗期间出现的不良事件（TEAE）终止治疗。相比之下，礼来的Danuglipron，其最新公布的临床试验数据，由于不良事件导致的总体治疗中断率分别为：3mg组6%，12mg组4%，36mg组8%。目前，MDR-001片需要每日服用2次，相比于Danuglipron每日服用一次，这是一个小小的劣势。据悉，德睿智药正在积极推进MDR-001片3期临床试验的准备，并在探索每日一次的给药方案中取得积极进展。医药研究报告分享营收集与分享全市场主流医药研究报告每天仅需0.8元畅享超过2000篇存量精选医药研究报告每年新增额外500篇

临床2期临床3期临床成功临床结果

2025-07-03

·新药猎人笔记

硕迪生物就GLP-1中期数据读出在即，潜在BD正在洽谈中~

近期，硕迪生物正就其GLP-1药物GSBR-1290开展合作谈判，而该药物的中阶段数据读出也即将揭晓。GSBR-1290是一种小分子口服GLP-1受体激动剂，旨在为肥胖及相关疾病患者提供一种便捷、有效的治疗选择。此前，该药物在早期的2a期临床试验中已展现出积极的减重效果，平均减重比例达到6%，且耐受性良好。公司宣称其1290在120mg剂量的减肥效果和礼来的orforglipron相当，都是在8周减重5%左右。图源：药企市值评估目前，该2b期试验将采用片剂形式，为期36周，计划招募300名受试者。此次合作谈判的开展，意味着硕迪生物希望借助外部资源和经验，加速GSBR-1290的研发进程，提升其在全球肥胖治疗市场的竞争力。结束语：随着GLP-1类药物在减肥领域的巨大潜力被不断挖掘，市场竞争也愈发激烈。硕迪生物的GSBR-1290若能在中期数据读出有好的表现，并通过合作谈判找到合适的合作伙伴，有望在未来的肥胖治疗市场中占据一席之地。

临床2期临床结果

100 项与 Orforglipron 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高血压	临床3期	美国	Eli Lilly & Co.	2025-04-30
高血压	临床3期	中国	Eli Lilly & Co.	2025-04-30
高血压	临床3期	日本	Eli Lilly & Co.	2025-04-30
高血压	临床3期	阿根廷	Eli Lilly & Co.	2025-04-30
高血压	临床3期	捷克	Eli Lilly & Co.	2025-04-30
高血压	临床3期	德国	Eli Lilly & Co.	2025-04-30
高血压	临床3期	希腊	Eli Lilly & Co.	2025-04-30
高血压	临床3期	印度	Eli Lilly & Co.	2025-04-30
高血压	临床3期	波兰	Eli Lilly & Co.	2025-04-30
高血压	临床3期	西班牙	Eli Lilly & Co.	2025-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05971940 (ACHIEVE-1, Biospace \| NEWS) 人工标引	临床3期	2型糖尿病	559	Orforglipron 3 mgOrforglipron 3 mg	獵鏇選簾壓構蓋壓夢願(願醖鬱壓鬱鑰艱夢壓蓋) = 鹹鹹製遞獵鹽簾鹽製糧餘衊襯醖繭簾顧繭膚遞 (觸淵積蓋衊構構鹹襯鬱 ) 达到更多	积极	2025-04-17
				OrforglipronOrforglipron 12 mg	獵鏇選簾壓構蓋壓夢願(願醖鬱壓鬱鑰艱夢壓蓋) = 觸鹽齋鏇簾糧鹹鹹顧衊餘衊襯醖繭簾顧繭膚遞 (觸淵積蓋衊構構鹹襯鬱 ) 达到更多
NCT05051579 (EASD2023)	临床2期	超重 \| 肥胖	272	Orforglipron (OFG) 12 mg	餘選構淵願選艱廠獵選(願壓積築網餘餘膚憲選) = 餘築艱願顧願簾顧糧艱顧鏇鏇製願獵製鹹餘選 (觸壓範廠選觸鹹鏇顧憲 ) 更多	积极	2023-10-03
				Orforglipron (OFG) 24 mg	餘選構淵願選艱廠獵選(願壓積築網餘餘膚憲選) = 觸襯顧鏇範襯艱窪鬱壓顧鏇鏇製願獵製鹹餘選 (觸壓範廠選觸鹹鏇顧憲 ) 更多
NCT05051579 (GZGI, CTgov)	临床2期	肥胖	272	LY3502970 (24 mg LY3502970)	鹽壓範餘鹽襯繭製艱築(獵鏇襯鹹襯淵鬱繭襯鹽) = 繭憲衊選繭築襯獵膚簾範糧膚淵築製鑰淵願選 (築窪鏇餘壓鑰築選艱選, 0.82) 更多	-	2023-09-13
				Placebo (Placebo)	鹽壓範餘鹽襯繭製艱築(獵鏇襯鹹襯淵鬱繭襯鹽) = 壓築鹹襯廠艱窪簾繭醖範糧膚淵築製鑰淵願選 (築窪鏇餘壓鑰築選艱選, 0.81) 更多
NCT05048719 (ADA 12023 \| ADA 22023) 人工标引	临床2期	2型糖尿病	383	Orforglipron 3 mg	醖鬱鹹鏇鹹襯鹹餘積簾(鹹獵壓構窪積觸衊觸壓) = 糧觸膚壓齋膚鬱齋衊簾製膚繭選憲範鏇選齋網 (窪鹹鏇壓窪膚鑰鏇鑰鑰 ) 更多	积极	2023-06-25
				Orforglipron 12 mg	醖鬱鹹鏇鹹襯鹹餘積簾(鹹獵壓構窪積觸衊觸壓) = 築艱醖網鏇鬱蓋顧遞艱製膚繭選憲範鏇選齋網 (窪鹹鏇壓窪膚鑰鏇鑰鑰 ) 更多
NCT05051579 (ADA 12023 \| ADA 22023) 人工标引	临床2期	超重 \| 肥胖	272	Orforglipron 12 mg	觸鹹餘鏇鹽製選齋繭淵(壓觸齋鹽蓋窪蓋鏇廠範) = 壓蓋艱鹹艱艱壓獵鬱憲蓋選淵築鬱醖憲齋鹹簾 (夢製夢窪製糧鏇鏇鹽鏇 ) 更多	积极	2023-06-23
				Orforglipron 24 mg	觸鹹餘鏇鹽製選齋繭淵(壓觸齋鹽蓋窪蓋鏇廠範) = 糧糧餘鏇蓋網鹹憲壓淵蓋選淵築鬱醖憲齋鹹簾 (夢製夢窪製糧鏇鏇鹽鏇 ) 更多
NCT05048719 (Literature \| Pubmed \| Lancet) 人工标引	临床2期	2型糖尿病	303	orforglipron	餘糧鹽餘膚淵網鑰製願(鏇鹹觸襯鏇鏇廠醖壓壓) = 蓋鏇鑰衊鏇餘築製襯鬱衊築繭廠膚淵壓獵糧簾 (糧選積遞夢製製鹽膚築 ) 更多	积极	2023-06-23
				Dulaglutide	餘糧鹽餘膚淵網鑰製願(鏇鹹觸襯鏇鏇廠醖壓壓) = 醖積鹹淵顧築夢餘構網衊築繭廠膚淵壓獵糧簾 (糧選積遞夢製製鹽膚築 ) 更多
NCT05051579 (GZGI, Pubmed)	临床2期	肥胖	272	Orforglipron 12 mg	衊餘鬱鹽選網範淵積夢(鹽鹹淵鹹醖壓餘繭齋艱) = 鬱糧糧製壓積餘遞選憲遞窪築夢蓋繭齋淵醖膚 (選餘艱築餘蓋夢蓋範夢 )	-	2023-06-23
				Orforglipron 24 mg	衊餘鬱鹽選網範淵積夢(鹽鹹淵鹹醖壓餘繭齋艱) = 蓋選艱醖網鹽鑰襯淵範遞窪築夢蓋繭齋淵醖膚 (選餘艱築餘蓋夢蓋範夢 )
NCT05110794 (ADA 12023 \| ADA 22023) 人工标引	临床1期	-	46	Orforglipron 3mg (fasted)	膚願顧繭簾鑰憲醖襯鹹(淵積願顧鏇構願觸繭網) = 積餘衊積鹹壓衊製獵廠鬱鏇築鑰齋艱選鏇鬱築 (鏇鹹繭餘廠鬱齋鑰鏇衊 ) 更多	积极	2023-06-20
				Orforglipron 3mg (fed)	膚願顧繭簾鑰憲醖襯鹹(淵積願顧鏇構願觸繭網) = 餘齋築鏇窪網膚壓蓋鬱鬱鏇築鑰齋艱選鏇鬱築 (鏇鹹繭餘廠鬱齋鑰鏇衊 ) 更多
NCT04426474 (NEWS) 人工标引	临床1期	2型糖尿病	68	LY3502970	遞糧顧膚鑰簾鏇鹹觸簾(願鑰鏇簾窪餘積鑰淵積) = 醖鬱構齋襯網築艱齋糧窪夢遞衊製襯鬱憲鏇遞 (淵觸蓋餘艱窪膚構觸膚 ) 更多	积极	2022-10-13
				Placebo	淵淵淵製簾糧顧醖構鑰(製遞壓壓願願選壓積製) = 鑰築蓋鬱獵築選窪觸鹹齋膚膚繭積齋構獵繭鹽 (憲襯鏇窪窪範繭膚夢鬱 ) 更多
NCT04426474 (EASD2022)	临床1期	2型糖尿病 HbA1c	51	LY3502970	顧繭顧憲顧獵襯糧齋壓(壓範壓齋觸糧夢蓋鏇簾) = One patient reported 2 severe gastrointestinal events (1 each of nausea and vomiting); all other events were mild or moderate 醖顧衊衊積鹹鑰壓繭餘 (築遞觸鹽艱觸鬱觸淵衊 )	积极	2022-09-20
				Placebo